| ADME | Absorption, distribution, metabolism, and excretion |
| ANDA | Abbreviated new drug application |
| API | Active pharmaceutical ingredient |
| BLA | Biologics license application |
| BPCA | Best Pharmaceuticals for Children Act of 2002 |
| CGMP | Current Good Manufacturing Practice |
| CINV-MEC | Chemotherapy-induced nausea and vomiting |
| CRL | Complete response letter |
| DQSA | Drug Quality and Security Act of 2013 |
| FDAMA | Food and Drug Administration Modernization Act of 1998 |
| IND | Investigational new drug |
| NCE | New chemical entity |
| NDA | New drug application |
| NICHD | National Institute for Child Health and Human Development |
| NME | New molecular entity |
| PK | Pharmacokinetic |
| PREA | Pediatric Research Equity Act of 2003 |
| PRV | Rare Pediatric Disease Priority Review Voucher Program of 2012 |
| PSP | Pediatric study plan |
| RCT | Randomized clinical trial |
| sNDA | Supplementary NDA |
| US-FDA | United States Food and Drug Administration |